Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients

Cancer Science

Volumn 107, Issue 12, 2016, Pages 1730-1735

  Ogiya, Rin ^a   Niikura, Naoki ^a   Kumaki, Nobue ^a   Bianchini, Giampaolo ^b   Kitano, Shigehisa ^c   Iwamoto, Takayuki ^d   Hayashi, Naoki ^e   Yokoyama, Kozue ^a   Oshitanai, Risa ^a   Terao, Mayako ^a   Morioka, Toru ^a   Tsuda, Banri ^a   Okamura, Takuho ^a   Saito, Yuki ^a   Suzuki, Yasuhiro ^a   Tokuda, Yutaka ^a  

^a TOKAI UNIVERSITY   (Japan)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^e ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

Author keywords

Immune microenvironment; immunohistochemistry; metastatic breast tumor; primary breast tumor; tumor infiltrating lymphocytes

Indexed keywords

ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HLA ANTIGEN CLASS 1; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; TRANSCRIPTION FACTOR FOXP3; BIOLOGICAL MARKER;

ADULT; ARTICLE; BONE MARROW METASTASIS; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISTANT METASTASIS; EARLY CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPAN; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTATIC BREAST CANCER; MUSCLE METASTASIS; PRIMARY BREAST CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; REGIONAL METASTASIS; RETROSPECTIVE STUDY; SKIN METASTASIS; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; TUMOR ESCAPE; TUMOR GROWTH; UNIVERSITY HOSPITAL; BIOPSY; BREAST NEOPLASMS; CANCER GRADING; CANCER STAGING; FEMALE; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY;

ADULT; BIOMARKERS; BIOPSY; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING;

EID: 85007335629     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.13101     Document Type: Article

References (35)

1. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007; 9(4): 212.
2. Schmidt M, Bohm D, von Torne C et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008 (Jul 1); 68: 5405–13.
3. Denkert C, Loibl S, Noske A et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010 (Jan 1); 28(1): 105–13.
4. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 2011; 13(6): R126.
5. Ono M, Tsuda H, Shimizu C et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat 2012 (Apr); 132: 793–805.
6. Yamaguchi R, Tanaka M, Yano A et al. Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum Pathol 2012 (Oct); 43: 1688–94.
7. Lee HJ, Seo JY, Ahn JH, Ahn SH, Gong G. Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer 2013 (Mar); 16(1): 32–9.
8. Loi S, Sirtaine N, Piette F et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013 (Mar 1); 31: 860–7.
9. Adams S, Gray RJ, Demaria S et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014 (Jul 28); 32: 2959–66. PubMed PMID: 25071121. Epub 2014/07/30. Eng.
10. Denkert C, von Minckwitz G, Brase JC et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 2014 (Dec 22); 33: 983–91. PubMed PMID: 25534375. Epub 2014/12/24. Eng.
11. Loi S, Michiels S, Salgado R et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 2014 (Aug); 25: 1544–50.
12. Perez EA, Thompson EA, Ballman KV et al. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol 2015 (Jan 20); 33: 701–8. PubMed PMID: 25605861. Epub 2015/01/22. Eng.
13. Leong PP, Mohammad R, Ibrahim N et al. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. Immunol Lett 2006 (Feb 15); 102: 229–36.
14. Miyashita M, Sasano H, Tamaki K et al. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 2014 (Dec); 148: 525–34.
15. Dieci MV, Criscitiello C, Goubar A et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol 2014 (Mar); 25: 611–8.
16. Burstein HJ, Lacchetti C, Anderson H et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. J Clin Oncol 2016 (Feb 16); 34: 1689–701. PubMed PMID: 26884586.
17. Cimino-Mathews A, Ye X, Meeker A, Argani P, Emens LA. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. Hum Pathol 2013 (Oct); 44: 2055–63.
18. Sobottka B, Pestalozzi B, Fink D, Moch H, Varga Z. Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases. Oncoimmunology 2016 (Jun); 5(6): e1153208.
19. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002 (Nov); 3: 991–8.
20. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007 (May); 121(1): 1–14.
21. Moossdorff M, van Roozendaal LM, Strobbe LJ et al. Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research. J Natl Cancer Inst 2014 (Dec); 106(12): dju288. PubMed PMID: 25381395. Epub 2014/11/09. Eng.
22. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011 (Aug); 22: 1736–47.
23. Salgado R, Denkert C, Demaria S et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015 (Feb); 26: 259–71.
24. Amir E, Miller N, Geddie W et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012 (Feb 20); 30: 587–92.
25. Simmons C, Miller N, Geddie W et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 2009 (Sep); 20: 1499–504.
26. Thompson AM, Jordan LB, Quinlan P et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 2010; 12(6): R92.
27. Niikura N, Liu J, Hayashi N et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2012 (Feb 20); 30: 593–9.
28. Loi S, MacCallum P. Host antitumor immunity plays a role in the survival of patients with newly diagnosed triple-negative breast cancer. J Clin Oncol 2014 (Sep 20); 32: 2935–7.
29. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015 (Oct 22); 373: 1627–39.
30. Weber JS, D'Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015 (Apr); 16: 375–84.
31. Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015 (Nov 5); 373: 1803–13.
32. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015 (Apr 3); 348(6230): 56–61.
33. Arato T, Daimon T, Heike Y et al. Guidance on cancer immunotherapy development in early-phase clinical studies. Cancer Sci 2015 (Dec);106(12):1761–71. PubMed PMID: 26767933. Pubmed Central PMCID: 4714668. Epub 2016/01/16. eng.
34. Champiat S, Ileana E, Giaccone G et al. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J Thorac Oncol 2014; 9: 144–53.
35. Salgado R, Denkert C, Campbell C et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol 2015 (Jul); 1: 448–54.